Metagenomi Therapeutics (MGX) Cash from Operations (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Cash from Operations of 21175000.0 for Q1 2026, up 7.3% year-over-year from 19734764.78 in Q1 2025, and up 10.07% quarter-over-quarter from 23546000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Cash from Operations (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Cash from Operations for 4 consecutive years, with 21175000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 7.3% year-over-year to 21175000.0; the TTM figure through Mar 2026 stood at 87225000.0 (up 14.54% YoY), while the FY2025 annual figure was 88892000.0, up 18.5% from the prior year.
- Cash from Operations rose to 21175000.0 in Q1 2026 per MGX's latest filing, from 23546000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 20592000.0 in Q4 2023 and bottomed at 29850000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 23888384.62 across 4 years, with a median of 23546000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 42.18% — and 2025, when it grew 23.48%.
- Metagenomi Therapeutics' Cash from Operations stood at 20592000.0 in 2023, then slipped by 27.6% to 26276000.0 in 2024, then advanced by 10.39% to 23546000.0 in 2025, then gained by 10.07% to 21175000.0 in 2026.
- Business Quant data shows MGX's Cash from Operations at 21175000.0 in Q1 2026, 23546000.0 in Q4 2025, and 21253000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | -19.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.51 Mn |
| Jun 30, 2026 | -19.51 Mn |
| Mar 31, 2026 | -21.18 Mn |
| Mar 31, 2026 | -21.18 Mn |
| Dec 31, 2025 | -23.55 Mn |
| Dec 31, 2025 | -23.55 Mn |
| Sep 30, 2025 | -21.25 Mn |
| Sep 30, 2025 | -21.25 Mn |
| Jun 30, 2025 | -21.25 Mn |
| Jun 30, 2025 | -21.25 Mn |
| Mar 31, 2025 | -22.84 Mn |
| Mar 31, 2025 | -22.84 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Sep 30, 2024 | -26.64 Mn |
| Sep 30, 2024 | -26.64 Mn |
| Jun 30, 2024 | -26.31 Mn |
| Jun 30, 2024 | -26.31 Mn |
| Mar 31, 2024 | -29.85 Mn |
| Mar 31, 2024 | -29.85 Mn |